Carbamylated hemoglobin: A potential marker for the adequacy of hemodialysis therapy in end-stage renal failure  by Davenport, Andrew et al.
Kidney International, Vol. 50 (1996), pp. 1344—1351
TECHNICAL NOTE
Carbamylated hemoglobin: A potential marker for the adequacy
of hemodialysis therapy in end-stage renal failure
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Departments of Renal Medicine and Clinical Chemistiy, Southmead Hospital, Bristol, England, United Kingdom
Carbamylated hemoglobin: A potential marker for the adequacy of
hemodialysis therapy in end-stage renal failure. Urea can dissociate in
vivo to form isocyanic acid which can react with hemoglobin to form
carbamylated hemoglobin. Previous work has shown that formation of
carbamylated hemoglobin depends upon both the severity and the dura-
tion of renal failure. To determine whether carbamylated hemoglobin can
be used as an assessment of the adequacy of hemodialysis treatment, we
prospectively studied 55 stable patients who regularly attended our
hospital dialysis program. Carbamylated hemoglobin was greater in those
patients with a Kt/V of 1.1 compared to those with a Kt/V of > 1.1
(120 8 sgVH/gHb versus 99 7, P < 0.01), and there was a negative
correlation with Kt/V (r =
—0.37, P = 0.007). There were positive
correlations between carbamylated hemoglobin and the time-averaged
urea concentration (r = 0.4, P = 0.004), and a negative correlation with
the urea reduction ratio (r =
—0.37,P = 0.01). Carbamylated hemoglobin
may therefore be a useful marker of the degree of uremia, just as
glycosylated hemoglobin is used in the assessment of patients with
diabetes mellitus.
Urea is one of many metabolites that accumulates in renal
failure [1]. Under physiological conditions urea can spontaneously
dissociate into ammonia and cyanate [2]. The reactive form of
cyanate, isocyanic acid, can react and form stable compounds with
both a and /3 amino groups of proteins and suiphydryl groups to
produce a stable adduct [3]. The terminal valine group of both the
a and /3 hemoglobin chains can thus undergo carbamylation by
this nonenzymatic post-translational chemical process to form
carbamylated hemoglobin [4]. Following acid hydrolysis carbamy-
lated hemoglobin is broken down and the terminal adduct re-
leased, carbamyl valine, which converts to valine hydantoin under
acidic conditions (Fig. 1). This can be measured by gas and high
performance liquid chromatography, and is used as a measure of
carbamylated hemoglobin [5, 61.
Although carbamylated hemoglobin has been the most studied
carbamylated protein, other plasma proteins and amino acids
have been shown to also undergo carbamylation in patients with
chronic renal failure [7, 8]. Several studies have reported that the
amount of carbamylated hemoglobin depends upon both the
duration of renal failure, being greatest in those subjects with
chronic renal failure compared to those with acute renal failure
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[9], and also the severity of the renal failure [10]. Similarly, as
renal function returns following successful renal transplantation,
carbamylated hemoglobin levels decline [10, 11].
Glycosylated hemoglobin is used by diabetologists to assess the
overall glycemic control of patients with diabetes mellitus, and it
has been suggested that the measurement of carbamylated hemo-
globin and or other carbamylated plasma proteins may be of
similar use in assessing the adequacy of dialysis treatment in
patients with end-stage renal failure [8, 12]. Currently, the ade-
quacy of hemodialysis treatment is assessed by the general well
being of patients on a chronic dialysis programme coupled with
assessment of urea removal during dialysis as measured by Kt/V
[131 and urea reduction ratio [141. The initial reports from the
National Co-operative Dialysis Study (NCDS) suggested that
patient survival and morbidity was dependent upon time-averaged
urea nitrogen concentrations and the adequacy of hemodialysis
treatment [15]. As conventional hemodialysis removes small but
not larger molecular weight solutes, many investigators have
queried whether the adequacy of hemodialysis can be judged
solely on the basis of urea removal [16], as short-term exposure to
high concentrations of urea may be asymptomatic [1]. Several
studies have shown that some uremic symptoms such as neurop-
athy and itching can be improved by increasing the adequacy of
hemodialysis, as judged by urea kinetic modeling rather than by
increasing the removal of so-called "middle molecules" [16, 17].
Increased urea removal during hemodialysis and a lower time
averaged urea concentration should result in less carbamylation of
hemoglobin and other plasma and intracellular proteins, so
reducing the affect of potential "uremic toxins."
To investigate whether carbamylated hemoglobin could act as
an assessment of adequate hemodialysis treatment, we prospec-
tively studied stable patients on our hospital hemodialysis pro-
gram.
Methods
Patients
This study was approved by the local hospital ethical commit-
tee. Fifty-five healthy stable patients with end-stage renal failure
attending our hospital hemodialysis program were studied. There
were 28 male and 27 female patients, mean age 58 years (saM 2.2),
who had been on the hemodialysis program for a mean of 26
months (range 6 to 120). No patient studied had diabetes mellitus,
malignancy or renal failure secondary to an autoimmune condi-
tion. Similarly, no patient was prescribed steroids and/or any other
drugs known to interfere with protein metabolism. No patient
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Fig. 1. Schematic representation of spontaneous in vivo dissociation of urea into isocyanic acid and the formation of carbamyl valine. Abbreviation Hb is
hemoglobin.
studied had received a blood transfusion, or suffered a septic
illness in the three months prior to the study. Thirty patients
(55%) were in receipt of erythropoietin. All patients had been
taking erythropoietin for a minimum of six months and had been
on a stable maintenance dose for at least eight weeks prior to the
study, median dose 3,000 lU/week (range 1,000 to 6,000).
All patients dialyzed three times a week with a standard dialysis
prescription, using a ccllulosic hollow fiber dialyzer (GFE 9/11,
Gambro, Lund AB, Sweden; or Asahi AM5OIAM65, Asahi,
Frankfurt, Germany). The median duration of each dialysis
session was four hours (range 3 to 5). All patients were dialyzed
with a Cobe Century 2 dialysis machine (Cobe, Quedgeley, UK),
using bicarbonate buffered dialysate with a flow rate of 500 ml/min
and a median blood pump speed of 250 mI/mm (range 200 to 350).
Heparin anticoagulation was used in all treatments.
Methods
Patients either dialyzed Monday, Wednesday and Friday or
Tuesday, Thursday and Saturday. Pre- and post-dialysis blood
samples were taken either on the Wednesday or Thursday, and a
predialysis sample also taken prior to the following dialysis
treatment. Urine from those patients with a urine output was also
obtained. Urea and creatinine were measured using standard
methodologies (SMAC III analyser; Bayer, Basingstoke, UK).
Urea kinetic data were determined using a computer based model
(Theraps; Cobe laboratories, Quedgeley, UK).
The blood samples were also analyzed for hemoglobin
(STACKR; Coulter Electronics, Luton, UK) and an EDTA
sample for the estimation of carbamylated hemoglobin taken with
the predialysis blood urea sample. Red blood cells were sepa-
rated, washed then hydrolysed with a mixture of concentrated
hydrochloric and acetic acids [6]. Carbamyl valine thus released
was immediately and quantitatively converted to valine hydantoin,
which was extracted and quantitated by high performance liquid
chromatography. Chromatography was performed under isocratic
conditions using a 1050 series liquid chromatograph (Hewlett
Packard, Winnersh, UK), and an Apex 2 (bonded octadecyl silica)
analytical column (Jones Chromatography, Hengoed, UK). The
between assay coefficient of variation was 10% at 0.91 .tg/liter
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valine hydantoin (equivalent to 113 ig valine hydantoin per gram
of hemoglobin in patients with chronic renal failure).
Statistical analysis
The Mann Whitney U-test and the Chi square test, with Yates'
correction if appropriate, were used to analyze data. Spearman's
rank correlation test was used for simple correlation, and multiple
regression analysis with Statview 512+ (Apple Macintosh mc,
Cupertino, CA, USA), a P value of less than 0.05 being considered
as significant. All data are presented as mean (± SCM), unless
otherwise stated.
Variable Mean
Standard
deviation
Coefficient of
variation
CHb 106.5 38.2 35.9
VH 906.8 325.3 35.9
Kt/V 1.24 0.23 18.5
URR 64.8 11.8 18.3
TACurca 413.6 99.7 24.1
Coefficient of variation Kt/V URR CHb
Mean (X) 15.4 14.9 14.0
Standard deviation (SD) 7.5 7.1 3.2
Range 8—24.3 7.3—22.6 10—18
SD/X x 100 49 41 22
Results
Validation of carbamylated hemoglobin
To establish the usefulness of carbamylated hemoglobin as a
marker for uremia we measured carbamylated hemoglobin in 70
patients attending the general nephrology clinic who had stable
chronic renal impairment ( 5% change in serum creatinine in
the previous 3 months). There were significant positive correla-
tions with both the serum urea and creatinine (Fig. 2).
A normal range was established by measuring carbamylated
hemoglobin in 27 patients with normal renal function, mean value
24.6 1.6 ig valine hydantoin/g Hb.
Interpatient variability
The mean total carbamyl valine for the study group was 920
44 .tg/dl and the carbamylated hemoglobin (carbamyl valine
corrected for hematocrit) 106.5 5.2 j.g valine hydantoin/g Hb,
significantly greater than the controls with normal renal function
(P < 0.001). The predialysis serum urea and creatinine concen-
trations were 27.4 0.8 mmol/liter and 1017 29 smol/liter,
respectively. Patient dry weights ranged from 30.5 to 114.8 kg,
with a mean of 67.4 2.3 kg, and the predialysis serum creatinine!
dry weight ratio was 15.9 0.6 jimol liter1 kg* Adequacy of
dialysis, as assessed by TACUrCa (time averaged urea), urea
reduction ratio (URR) and Kt/V are set out in Table 1.
intrapatient variability
To assess interpatient variability carbamylated hemoglobin was
measured serially over a six month period in four stable patients
in whom there were no changes in dialysis prescription, and the
variability compared with that of the comparable monthly Kt/V
and URR values (Table 2).
Carhamylated hemoglobin as an assessment of uremia
There was no statistically significant positive correlation be-
tween the predialysis serum urea and either carbamylated hemo-
globin (r = 0.23, P 0.08) or the total carbamyl valine (r = 0.29,
A
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Table 1. Interpatient variation in the study group for carbamylated
hemoglobin (CHb g VHJg Hb), total valine hydantoin (VH jrg/dl),
Kt/V, urea reduction ratio (URR %) and time averaged urea (TACurea
mmol . hr)
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Table 2. Interpatient variation on serial monthly estimations for
carbamylated hemoglobin (CHb), Kt/V and urea reduction ratio (URR)
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Fig. 2. Positive correlations were obtained for both (A) serum urea and
creatinine and (B) carbamylated hemoglobin in 70 stable patients with
chronic renal failure attending the general nephrology outpatient department.
A. y = 3.735x + 26.033, r = 0.771; P < 0.001. B. y = 1.37x + 43.920, r =
0.734, P < 0.001.
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Fig. 3. Positive correlations were obtained between the time averaged urea
concentration (TAG urea) and both (A) carbamylated hemoglobin (CHb)
and (B) the total carbamyl valine. A. y = 58.247' 10O0, r = 0.371, P <
0.05. B. y = 405.816• 10000l, r = 0.483, P < 0.001.
P 0.03), or the predialysis serum creatinine (r = 0.24, P = 0.08
and r = 0.170, P = 0.9, respectively).
Using the time averaged concentration of urea (TACUr) and
the urea reduction ratio (URR) as an assessment of the adequacy
of dialysis treatment, then there were positive correlations with
both carhamylated hemoglobin and total carbamyl valine with
TACr,rca and negative correlations with the urea reduction ratio
(Figs. 3 and 4).
Taking arbitrary cut off points for Kt/V of 1.1 and 1.4, both the
total carbamyl valine and that corrected for hematocrit (carbamy-
lated hemoglobin) were significantly greater in those patients with
the lower Kt/V values (Fig. 5). There were negative correlations
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Fig. 4. Negative correlations were obtained for the urea reduction ratio
800 (URR) and both (A) carbamylated hemoglobin (GHb) and (B) the total
carbamyl valine. A. y = 1.77.135' r =
—0.295, P < 0.05. B. y =
1683.756 jQ_0005x, r =
—0.339, P < 0.01.
between Kt/V and both carbamylated hemoglobin and total
carbamyl valine (Fig. 6).
The study group was followed up for two years, during this
period ten patients (18.5%) died. Comparison of dialysis variables
and the use of erythropoietin, showed that only the carbamylated
hemoglobin was significantly different between the groups, being
greater in those whom subsequently died, suggesting that more
severe uremia is a predictor of death (Table 3).
Other factors affecting carbamylated hemoglobin
Age. Using multiple regression analysis, there were no correla-
tions between carbamylated hemoglobin and the sex of the
patient, weight, creatinine corrected for weight, duration of
dialysis. However, there was a correlation between the age of the
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Fig. 5. Taking arbitraiy cut off points for KtIV at 1.1 and 1.4, then for each
cut off point both the (A) carbamylated hemoglobin and the (B) total
carbamyl valine were significantly greater in the group with the greater KtIV
and therefore less efficient dialysis. A. y 197.488 10_0238, r = —0.356,
P < 0.001. B. y 2167.831 l0_032), r = —0.470, P <0.001.
Fig. 6. Negative correlations were obtained for Kt/V and both (A) carbamy-
lated hemoglobin (CHb) and (B) total carbamyl valine. Symbols are: (B)
Kt/V < 1.1; () Kt.V> 1.1; (LI) Kt/V < 1.4; (B) Kt/V> 1.4; P < 0.01.
Table 3. Dialysis adequacy in the ten patients who died during follow-
up and the forty-four survivors
Variable Survivors Non-survivors P value
Kt/V 1.25 (0.035) 1.15 (0.067) 0.12
TACuroa 413 (15) 416 (35) 0.68
URR 65.4 (1.7) 61.3 (4.7) 0.21
CHb 100.1 (5.1) 134.5 (14) <0.02
VH 869.5 (47.5) 1070.6 (106) 0.08
Values expressed as means (sEM)
Carbamylated hemoglobin (CHb pg VH/g Hb), total valine hydantoin
(VH jLg/dl), Kt/V, urea reduction ratio (URR %) and time averaged urea
(TAC=ca mmol . hr).
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patient and both carbamylated hemoglobin and total carbamyl
valine (Fig. 7).
Etythropoietin therapy. Thirty patients, 16 male, 14 female, had
been prescribed erythropoietin and all were on stable mainte-
nance doses. There were no differences between the groups in
terms of hematocrit and adequacy of hemodialysis therapy (Table
4). The mean corpuscular volume was greater, but not statistically
different in the erythropoietin group, 90.5 0.9 fi versus 88.3
tO fi. However, both the mean corpuscular hemoglobin and
reticulocyte Count were greater in the erythropoietin group
(31.0 0.4 pg vs. 30,3 0.4 pg, P K 0.05 and 1.7 0.1% versus
1.3 0,18%, P < 0.05, respectively). Carbamylated hemoglobin
was greater in the group not prescribed erythropoietin (P = 0.03).
Total carbamyl valine was also greater in those not prescribed
erythropoietin, but the difference was not statistically significant
(Table 4). Those patients not prescribed erythropoietin were
slightly older and heavier than the erythropoietin group, but the
differences were not significant. During follow-up the number of
deaths was not significantly different between those patients
prescibed erythropoietin or not.
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Age, years
Fig. 7. Positive correlations were obtained between the age of the patient and
both (A) carbamylated hemoglobin (CHh) and (B) total carbamyl valine. A.
y = 63.647 1O0003, r = 0.367, P < 0.01. B. y = 523.768 1O0004, r = 0.374,
P < 0.01.
Diabetes mellitus
Carbamylated hemoglobin was also measured in seven diabetic
regular hemodialysis patients and compared to seven of the study
group, matched for age, erythropoietin and adequacy of dialysis,
as assessed by Kt/V. Although there were no statistical differences
between the groups, the carbamylated hemoglobin was slightly
lower in the diabetic group, whereas the valine hydantoin was
slightly greater (Table 5).
Discussion
The prescription of hemodialysis treatment is empirical in most
cases, and based on clinical judgemcnt. With the advent of the
Erythropoietin
group
No eiythropoictin
group
Age years 55.0 3.1 62.2 3.1
Hemoglobin gld! 8.74 0.2 8.39 0.4
Dry weight kg 64.3 3.3 71.3 2.9
Predialysis serum urea 28.7 1.1 25.8 1.2
mmol/liter
Kt/V 1.24 0.04 1.16 0.04
TACuea mmol/liter 17.5 0.7 16.6 0.9
Urea reduction ratio % 65.1 2.7 63.2 3.0
Carbamylated hemoglobin 95.8 5.6 119.9 8.3"
pgVH/g Hb
Carbamyl valine pg/liter 8.5 0.5 10.2 0.7
Table 5. Effect of diabetes mellitus on carbamylatcd hemoglobin (CHb
pg VH/g Hb), total valine hydantoin (VH ,i.Lg/dl), Kt!V, urea reduction
ratio (URR %)
Variable Diabetic Non-diabetic
CHb 93.1 (13.2) 106.9 (14.9)
VH 856.6 (109) 803.1 (120)
Kt/V 1.26 (0.097) 1.26 (0.097)
URR 63.5 (3.2) 63.4 (2.0)
National Cooperative Dialysis Study, mathematical models have
become increasingly recognized as a valuable adjunct in determin-
ing the amount of dialysis therapy any individual patient requires
[18]. However, formal urea kinetic modeling has been criticized as
being impracticable in a busy hospital-based dialysis program, and
that more simplified mathematical models can be used [19]. Some
of these simplified models utilize the urea reduction ratio, and
indeed the urea reduction ratio has been advocated by other
investigators as a means of assessing dialysis adequacy in its own
right [20]. Whereas other workers have shown that there are
differences in the amount of hemodialysis delivered when formal
urea kinetic modeling and the urea reduction ratio are compared
[21]. Similarly, errors can be made in calculating formal urea
kinetics due to variety of factors including reduction in blood!
dialysate flow rates, effective dialyzer clearance and recirculation
[13, 22]. An alternative index of adequacy of hemodialysis would
therefore be helpful. Thus, the measurement of carbamylated
hemoglobin, an index of urea accumulation, may have a possible
role in the clinical management of patients, similar to the way that
glycosylated hemoglobin is used in the monitoring of patients with
diabetes mellitus.
Interpatient and intraparient variability
We have previously demonstrated that carbamylated hemoglo-
bin can be of use in differentiating acute from chronic renal
failure, as the carbamylation of hemoglobin depends upon both
the degree and the duration of uremia [9]. In this study of stable
regular hemodialysis patients the interpatient coefficients of vari-
ation of KIN and the urea reduction ratio, were similar (18%)
and less than those for time averaged urea (24%) and both
carbamylated hemoglobin and total valinc hydantoin (36%). By
having a greater interpatient coefficient of variation, carbamylated
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Table 4. Comparison between the 30 patients stabilized on
erythropoietin therapy and the other 25 hospital hemodialysis patients
U
-Q0
C)
ft
Ca0
Ct
-C
a)
0)0
-J
200
150
100
50
0
1000
100
P < 0.05 vs. erythropoietin group
0 20 40 60 80 100
Age, years
B
S
.S
S S
Values are expressed as means (sEM).
'S
SSS.,
S
0 20 40 60 80 100
1350 Davenport ci at: Dialysis adequacy and carbamylated hemoglobin
hemoglobin and valine hydantoin could potentially be better
discriminats in assessing the degree of uremia than Kt/V and
URR, which had a much smaller spread of values. When it came
to assesing intrapatient variability, there was much greater vari-
ability with Kt/V than carbamylated hemoglobin when studied
serially over a six month follow-up period, when no changes had
been made to the dialysis prescription. Intrapatient variability of
Kt/V is well recognized due to both technical problems with the
single dialysis session and to patient non-compliance during
dialysis when the measurements were made [13, 221. Whereas
carbamylated hemoglobin provides a greater intrapatient stability
in the assessment of uremia, as one would expect from earlier
studies, which have shown that it is not affected by a single
hernodialysis treatment and that it takes some two weeks or more
to decline following successful renal allograft transplantation [23].
Assessment of adequacy of dialysis treatment
In this study there was no correlation between carbamylated
hemoglobin and the predialysis serum urea, and only a very weak
correlation with the total carbamyl valine. However, there were
positive correlations with the time averaged urea concentration.
This would suggest that carbamylation reflects the overall degree
of urea retention rather than peaks in urea concentration. These
data support the results of an earlier, smaller study based on
patients dialyzed twice a week [231.
In terms of adequacy of hemodialysis treatment, we compared
carbamylated hemoglobin and total carbamyl valine with the more
traditional assessments of dialysis adequacy. In addition to nega-
tive correlations between carhamylated hemoglobin and total
carbamyl valine and Kt/V, there were positive correlations with
the time averaged urea concentration and negative correlations
with the urea reduction ratio. Thus the data from this study
suggest that the measurement of carbamylated hemoglobin and/or
total carhamyl valine could be used as an independent variable to
assess the adequacy of dialysis. As carbamylated hemoglobin is
not affected by hemodialysis [23, 24], only one predialysis blood
sample would be required, compared to a minimum of three to
determine the time averaged urea concentration. Thus correla-
tions were greatest with time averaged urea and least with the
urea reduction ratio, confirming previous smaller reports [11, 25].
In terms of adequacy of hemodialysis treatment, taking arbi-
trary cut off values for Kt/V, those patients with the most adequate
dialysis had significantly lower concentrations of both carhamy-
lated hemoglobin and total carbamyl valine, compared to those
with the less efficient dialysis. More recently Stim and colleagues
suggested that a cut off point of  100 jg VH/g Hb could
differentiate those who were in receipt of good dialysis [25]. In our
series, patients with a Kt/V of < 1.1 had a mean carbamylated
hemoglobin of 99 1g VH/g Hb, which therefore is in agreement
with the work of Stim et al [251.
In the NCDS study there was increased mortality and morbidity
in the group of patients in receipt of inadequate dialysis. In our
series of patients there was an 18% mortality during the two years
of follow-up. Those patients who died had a significantly greater
carbamylated hemoglobin (135 j.tgVH/gHb)than those who sur-
vived, the mean value of the surviviors being 100 jigVH/gHb.
Oiher fttctors affecting carbamylation of hemoglobin
Although there were statistically significant correlations be-
tween carbamylated hemoglobin and the standard assessments of
dialysis adequacy, the correlations were not particularly tight,
although this may have been due the variability in Kt/V between
individual dialysis treatments caused either by technical problems
during dialysis (hypotension, variable blood pump speed) or
patient non-compliance, we investigated whether other factors
could affect the degree of carbamylation.
Previous work has questioned whether the kinetics of carbamy-
lation of red blood cells from elderly patients with uremia is
different from that in younger patients [24]. It is known that
glycosylation of red blood cells is increased in normal healthy
elderly subjects compared to younger subjects. In this study there
appeared to be a correlation between the age of patients and both
carbamylated hemoglobin and the total carbamyl valine. How-
ever, the older patients were less likely to have been prescribed
erythropoictin, and therefore this observation may be due both to
differences in the kinetics of carhamylation in older subjects, but
could also have been affected by changes in red blood cell life
span, as the in vitro carbamylation of aged red blood cells is
greater. Those patients stabilized on erythropoietin had a lower
carbamylated hemoglobin concentration and an increased reticu-
locyte count compared to those not prescribed erythropoietin,
suggesting an increased number of "young red cells" that may not
be so amenable to carbamylation [3]. This is in agreement with
earlier work that showed that the amount of carhamylated
hemoglobin was reduced in patients with sickle cell disease in
whom the red cell survival time was decreased, and also in
patients with an increased reticulocyte response [3, 4].
For this study we excluded diabetic subjects, however, the
amount of hemoglobin that is carbamylated is less than that which
can be glycosylated in diabetic subjects ( 0.02 vs. 6 to 10%). In
a small series of diabetic subjects with both dialysis dependent and
chronic renal failure, we were unable to show any significant
differences in the amount of carbamylation when compared to
nondiabetic patients with a similar degree of uremia. Although
advanced glycosylation end products (AGEs) are known to be
increased in both diabetic subjects with renal failure and those
nondiabetic patients with renal failure due to the reduction in
renal tubular catabolism, glycosylated hemoglobin has not been
shown to be increased in renal failure [10, 26]. Our findings,
although open to a type II statistical error, support the work of
others who were unable to demonstrate any increase in glycosy-
lated hemoglobin in uremic subjects [26].
Total carbamyl valine has been traditionally corrected for
hematocrit, to express the result as carbamylated hemoglobin [5].
These initial studies were based on patients with sickle cell disease
[3, 4] and the assumptions made in red blood cell life span may not
he appropriate for patients with end-stage renal failure [9]. In our
study the measurement of total carhamyl valine, when expressed
as a logarithm, was associated with better statistical correlations
with Kt/V, time averaged urea concentration and the urea reduc-
tion ratio than those found with carbamylated hemoglobin. Sim-
ilarly, the statistical correlation was better for total carbamyl
valine and the age of the patient compared to that with carbamy-
lated hemoglobin. In addition, there was no statistical difference
between total carhamyl valine between the crythropoietin group
and those not requiring erythropoietin, whereas there was for
carbamylated hemoglobin. Thus the determination of total car-
bamyl valine may be superior to that of carhamylated hemoglobin
in assessing the overall degree of urea retention, as it is less
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affected by changes in hemoglobin, and may be more responsive
to short-term changes in the degree of azotemia.
Currently the measurement of carbamylated hemoglobin and
other plasma and tissue proteins remains a research assay. Most
centers use a HPLC assay [9, 25] based on that of Kwan et al [6].
In our center batches of 12 samples are assayed, with a total
specimen preparation time of 80 minutes and then a sample
estimation time of 10 minutes, with a total cost of $9.00 per
sample. Others have reported a quicker method for HbA estima-
tion using a cation exchange liquid chromatography method with
an individual sample time of 15 minutes [26], hut no sample time
preparation was specified. Similarly, the intrassay and between
assay variation for carbamylated hemoglobin were not detailed
[26]. To bring what is potentially a clinically useful assay to the
bedside, the assay must be developed to reduce both the labora-
tory time and cost. Kraus and colleagues have pioneered other
techniques by developing a solid-phase competitive ELISA, by
raising polyclonal antisera to various carbamoyl proteins [27].
Therefore, in this study the measurement of carbamylated
hemoglobin and total carbamyl valine were found useful as
markers of the adequacy of hemodialysis treatment. As they are
related to urea accumulation, carbamylation may help to explain
the paradox of why the adequacy of dialysis and both patient
morbidity and mortality appear to depend upon the removal of
urea, a small molecular weight solute [15, 18, 19]. Carbamylation
of proteins may result in abnormal function [8] and the generation
of so-called "toxic middle molecules" [16]. Thus carbamylation
may have similarities to glycosylation in diabetes mellitus, and the
measurement of carbamylated hemoglobin and plasma proteins
be of use in clinical practice, just as glycosylated hemoglobin.
Reprint requests to Dr. A. Davenport, Department of Renal Medicine and
Transplantation, Royal Free Hospital, Pond Street, London NW3 2QG,
England, United Kingdom.
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